North America Pet Diabetes Care Market Size, Share, and Growth Forecast 2026 - 2033

The North America Pet Diabetes Care market size is expected to be valued at US$ 1.1 billion in 2026 and projected to reach US$ 1.8 billion by 2033, growing at a CAGR of 7.3% between 2026 and 2033.

The North America Pet Diabetes Care Market is developing as pet owners increasingly seek advanced solutions for managing chronic conditions in dogs and cats. The market includes insulin therapy, blood glucose monitoring devices, diabetes management supplies, and related services. Insulin therapy remains the leading segment, supported by its established role in diabetes management, while glucose monitoring is gaining importance as veterinary practices adopt home-based and continuous monitoring technologies. The region is also witnessing greater adoption of CGM solutions and updated clinical approaches. In 2026, AAHA guidelines highlighted expanded use of CGMs and updated insulin and glucose-monitoring recommendations for diabetic cats, supporting continued innovation in veterinary diabetes care.

Drivers - Rising Diagnosed Prevalence of Diabetes Mellitus Among Companion Dogs and Cats

The escalating diagnosed prevalence of diabetes mellitus among companion dogs and cats across North America represents a central force sustaining long-term demand for insulin therapy and ongoing diabetes management products, as the chronic nature of the condition requires lifelong daily treatment following diagnosis. The American Veterinary Medical Association has continued to highlight rising diagnosed diabetes cases among aging companion animals, reflecting both improved diagnostic detection and genuine prevalence increases tied to rising pet obesity rates. This sustained and growing diagnosed patient population ensures continuous insulin procurement and monitoring supply replenishment cycles across veterinary practices throughout the region. Companies including Zoetis Inc. and Merck Animal Health maintain extensive pet diabetes therapy portfolios that directly benefit from this expanding diagnosed animal population. The chronic, lifelong treatment requirement associated with pet diabetes continues to anchor stable, recurring demand across the broader North America pet diabetes care market.

Growing Pet Owner Willingness to Invest in Advanced Veterinary Care and Monitoring Technology

North American pet owners are increasingly willing to invest in advanced veterinary diagnostic and monitoring technology for chronic conditions such as diabetes, reflecting a broader cultural shift toward treating companion animals as family members deserving of comprehensive medical care. The American Pet Products Association (APPA) has continued to report rising annual pet care expenditure across U.S. households, with veterinary care and supplies representing a substantial and growing share of total spending. This willingness to invest in ongoing chronic disease management is directly translating into higher adoption of continuous glucose monitoring devices and home testing supplies that were previously reserved for specialty veterinary settings. Companies including IDEXX Laboratories, Inc. and Abbott Laboratories continue to expand veterinary-focused glucose monitoring technology to serve this growing pet owner demand, reinforcing the structural link between rising pet care investment and sustained diabetes management product adoption across North America.

Market Restraints - High Cost of Long-Term Insulin Therapy and Monitoring Supplies Limiting Owner Adherence

The cumulative cost of lifelong insulin therapy, syringes, and blood glucose monitoring supplies for diabetic pets creates a substantial ongoing financial burden for pet owners, particularly those without pet insurance coverage or access to veterinary payment assistance programs. The American Animal Hospital Association (AAHA) has continued to highlight cost as a leading barrier to consistent chronic disease management adherence among pet owners managing diabetic companion animals. This financial burden occasionally leads to treatment discontinuation, inconsistent dosing, or delayed monitoring supply replenishment, particularly among middle- and lower-income pet-owning households across North America. Because diabetes management requires indefinite ongoing treatment rather than a finite treatment course, the accumulated lifetime cost burden continues to constrain the pace at which all diagnosed pets receive consistently optimal diabetes management despite strong underlying clinical need across the region's veterinary care system.

Limited Pet Owner Awareness of Early Diabetes Symptoms Delaying Diagnosis and Treatment

Many North American pet owners remain unaware of the early warning signs of diabetes mellitus in dogs and cats, including increased thirst, urination, and weight loss, resulting in delayed veterinary consultation and diagnosis until the condition has progressed to more severe or complicated presentations. The American Veterinary Medical Association has continued to emphasize the importance of pet owner education regarding early diabetes symptom recognition as a key factor in improving treatment outcomes and reducing complication rates. This awareness gap disproportionately affects pets in households with less frequent veterinary visit patterns, occasionally resulting in diagnosis only after diabetic ketoacidosis or other serious complications develop, which can complicate initial treatment protocols and elevate overall care costs. This delayed-diagnosis pattern continues to constrain the market's ability to capture earlier-stage, less complex treatment revenue across the broader diabetic pet population.

Market Opportunities - Rising Adoption of Continuous Glucose Monitoring Technology Reducing Owner Testing Burden

Continuous and flash glucose monitoring devices are emerging as the fastest-growing product segment within the market, driven by growing veterinary and pet owner interest in technology that reduces the frequency of traditional blood draw-based glucose testing for diabetic companion animals. The American Animal Hospital Association has continued to highlight growing veterinary interest in adapting human continuous glucose monitoring technology for companion animal diabetes management, citing improved owner compliance and more comprehensive glucose trend data compared to traditional spot-check testing. Companies including Abbott Laboratories and i-SENS, Inc. continue to expand glucose monitoring technology offerings suited to veterinary applications. As veterinary adoption of continuous monitoring technology continues to mature, manufacturers that prioritize companion animal-specific device development and veterinary education stand to capture a disproportionate share of incremental category growth through the forecast period across North America.

Expansion of Online Pet Pharmacy Channels Supporting Chronic Medication Refill Convenience

The continued growth of online pet pharmacy platforms presents a meaningful opportunity for pet diabetes care manufacturers and distributors, as the chronic, lifelong nature of insulin therapy and monitoring supply replenishment makes diabetic pet owners particularly well-suited to automatic refill and home delivery pharmacy models. Growing consumer comfort with digital veterinary prescription fulfillment, supported by expanding telehealth veterinary consultation adoption across the United States and Canada, continues to reinforce demand for convenient online diabetes supply procurement. Companies such as Covetrus, Inc. and Trividia Health, Inc. continue to strengthen distribution partnerships with online pet pharmacy platforms to capture this shifting purchasing behavior. As online pet pharmacy adoption continues to expand among chronic disease pet owners seeking convenient, subscription-based supply access, diabetes care manufacturers that prioritize digital distribution partnerships stand to capture growing demand across increasingly digitally engaged pet owner populations.

Product Analysis

Insulin Therapy holds the leading position within the product category, commanding an estimated 41% share of the North America Pet Diabetes Care Market in 2025. This dominance is underpinned by insulin therapy's status as the foundational, non-substitutable treatment for both canine and feline diabetes mellitus, supported by treatment guidelines referenced by the American Animal Hospital Association that consistently recommend insulin as the primary therapeutic intervention following diagnosis.

Its lifelong treatment requirement, combined with the absence of viable substitute therapies for most diagnosed pets, continues to reinforce veterinary and pet owner reliance on consistent insulin procurement. Companies including Merck Animal Health and Boehringer Ingelheim Animal Health maintain extensive veterinary insulin product portfolios that anchor this segment's leadership. The chronic, non-negotiable nature of insulin dependency among diagnosed diabetic pets continues to sustain its position as the largest and most consistently purchased product category within the broader pet diabetes care market.

Animal Type Analysis

Dogs represent the leading animal type segment, accounting for an estimated 54% share of the market in 2025, reflecting the larger overall companion dog population across North America relative to cats, combined with rising diagnosed diabetes prevalence tied to canine obesity trends. The American Veterinary Medical Association continues to report dogs as the most commonly owned companion animal species across U.S. households, sustaining a large base of at-risk and diagnosed diabetic canine patients requiring lifelong insulin therapy and monitoring. This substantial diagnosed canine population drives consistent product demand across insulin therapy, monitoring devices, and management supplies throughout veterinary practices nationwide.

Companies including Zoetis Inc. and Elanco Animal Health Incorporated maintain strong canine-focused diabetes care portfolios that reinforce this segment's leadership. The scale of the diagnosed canine diabetic population continues to anchor dogs as the largest animal type contributor to overall pet diabetes care demand across North America.

Distribution Channel Analysis

Veterinary Hospitals & Clinics represent the leading distribution channel segment, capturing an estimated 48% share of the market in 2026, driven by their central role in diagnosing diabetes, initiating insulin therapy, and providing ongoing monitoring and dose adjustment services that cannot be replicated through retail or online channels alone.

Diagnosed diabetic pets typically require initial hospitalization or intensive outpatient monitoring to stabilize insulin dosing before owners transition to home-based management, reinforcing veterinary hospitals' central role in the treatment pathway. The American Animal Hospital Association continues to emphasize veterinary hospital-based diabetes management protocols as the clinical standard of care for newly diagnosed pets. Companies such as IDEXX Laboratories, Inc. and Dechra Pharmaceuticals PLC maintain strong veterinary hospital distribution and clinical engagement strategies. This central diagnostic and treatment-initiation role continues to anchor veterinary hospitals and clinics as the leading distribution channel within the North America pet diabetes care market.

United States Pet Diabetes Care Market Trends and Insights

The United States leads the North America Pet Diabetes Care Market, holding an estimated 82% share in 2025, supported by the country's large companion animal population and extensive veterinary care infrastructure tracked by the American Veterinary Medical Association. The country's high pet ownership rates, combined with rising veterinary care expenditure reported by the American Pet Products Association, continue to sustain consistent demand for insulin therapy, glucose monitoring devices, and diabetes management supplies across veterinary hospitals and retail channels nationwide.

Continued innovation within continuous glucose monitoring technology, supported by ongoing veterinary product development tracked across the country's animal health industry, further reinforces sustained domestic demand. Strong pet insurance penetration growth and expanding telehealth veterinary consultation adoption continue to anchor the United States' leadership position across both branded and generic pet diabetes care product categories throughout the forecast period.

Canada Pet Diabetes Care Market Trends and Insights

Canada is projected to register the fastest CAGR within North America between 2026 and 2033, driven by rising companion animal ownership, expanding veterinary care infrastructure, and growing pet owner willingness to invest in chronic disease management tracked by the Canadian Veterinary Medical Association. Statistics Canada has continued to report steady growth in household pet care expenditure, reinforcing sustained demand for veterinary diagnostic and diabetes management products across Canadian veterinary practices.

Expansion of veterinary specialty clinics and rising pet insurance adoption across major Canadian metropolitan areas continues to support accelerated diabetes care product adoption, positioning Canada for sustained above-average growth momentum through the forecast period relative to other North American markets. Growing awareness campaigns led by veterinary associations regarding early diabetes symptom recognition are further expected to support earlier diagnosis rates across the country.

The North America pet diabetes care market remains moderately consolidated, dominated by established animal health companies with extensive veterinary pharmaceutical and diagnostic portfolios. Companies are differentiating through continued investment in companion animal-specific glucose monitoring technology, expanded insulin product formulations, and strengthened veterinary distribution partnerships. Key differentiators among market leaders include long-standing veterinary relationships, established regulatory approvals from the FDA Center for Veterinary Medicine, and strong clinical research supporting product efficacy in companion animals. Emerging business model trends include veterinary telehealth partnerships and online pet pharmacy distribution agreements, as companies including Zoetis Inc. and IDEXX Laboratories, Inc. continue expanding North American manufacturing and distribution capacity to meet steady demand for pet diabetes management products.

Key Developments:

• In May 2026, ALR Technologies launched the GluCurve Pet CGM in Canada, a continuous glucose monitoring system specifically designed for diabetic cats and dogs. The sensor provides glucose readings every minute for up to 14 days, with data accessible through a mobile app for pet owners and a web portal for veterinarians.
• In April 2026, the American Animal Hospital Association (AAHA) released new cat-specific diabetes management guidelines covering diagnosis, treatment, insulin therapy, SGLT2 inhibitor use, dietary management, diabetic remission, and glucose monitoring.